The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Safety profile of anti-CD19 CAR T-cell therapy axicabtagene ciloleucel
A major concern surrounding novel therapeutics is their safety, which must be characterized thoroughly. Here, Sattva Neelapu, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the safety data regarding the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel; KTE-C19) from the long-term follow-up of the ZUMA-1 trial (NCT02348216). Dr Neelapu covers what the most common adverse events were, when they occurred and their reversibility. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
